theres no price on the documents provided. ralph has no evidence to backup the claims re pricing materially cheaper and its already an existing program GT500, from 2019 prospectus, so it doesnt add anything new to the investment case.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%